Not logged in Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers Rana R. McKay MD; Sumanta Pal MD; Wanling Xie MS; David Aggen MD, PhD; Laurence Albiges MD, PhD; Andrea Apolo MD; Michael B. Atkins MD; Rick Bangs MBA, PMP; Kathryn E. Beckermann MD, PhD; Joaquim Bellmunt MD, PhD; Stephanie A. Berg DO; Mehmet A. Bilen MD; David Braun MD, PhD; Maria I. Carlo MD; Jason Efstathiou MD, DPhil; Matthew Galsky MD; Petros Grivas MD, PhD; Shilpa Gupta MD; Naomi Haas MD; A. Ari Hakimi MD; Hans Hammers MD, PhD; Daniel Y. C. Heng MSC; Michelle Hirsch MD, PhD; Gopakumar Iyer MD; Eric Jonasch MD; Vadim S. Koshkin MD; Oleksandr Kryvenko MD; Bryan Lewis JD; Roger Li MD; Surena Matin MD; Benjamin Maughan MD, PharmD; David F. McDermott MD; Bradley McGregor MD; Joshua Meeks MD, PhD; Matthew Milowsky MD; Robert Motzer MD; Andrea Necchi MD; Dan Petrylak MD; Sima Porten MD, MPH; Thomas Powles MBBS, MRCP, MD; Brian Rini MD; Brian Shuch MD; Arlene Siefker-Radtke MD; Guru Sonpavde MD; S. Srikala Sridhar MD; Cristina Suarez MD, PhD; Chad Tang MD; Abhishek Tripathi MD; Michiel S. Van Der Heijden MD, PhD; Martin Voss MD; Wenxin Xu MD; Tian Zhang MD; Jonathan Rosenberg MD; Toni K. Choueiri MD Share Save
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms Reis, Henning; Al-Ahmadie, Hikmat; Gaisa, Nadine T.; Lopez-Beltran, Antonio; Maclean, Fiona; Tsuzuki, Toyonori; Werneck da Cunha, Isabela; Amin, Mahul B.; Aning, Jonathan; Aron, Manju; Athanazio, Daniel; Bambury, Richard M.; Cheng, Liang; Gopalan, Anuradha; Gulmann, Christian; Guo, Charles C.; Harris, Carole; Iyer, Gopa; Jimenez, Rafael E.; Jinzaki, Masahiro; Kikuchi, Eiji; Lal, Priti; Miyai, Kosuke; Netto, George J.; Pan, Chin-Chen; Panebianco, Valeria; van Rhijn, Bas W. G.; Siefker-Radtke, Arlene; Smith, Steven C.; Szarvas, Tibor; Wobker, Sara E.; Kristiansen, Glen; Paner, Gladell P. Share Save
Share Save
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011 O'Donnell, Peter H.; Loriot, Yohann; Csoszi, Tibor; Matsubara, Nobuaki; Shin, Sang Joon; Park, Se Hoon; Atduev, Vagif; Gumus, Mahmut; Karaca, Saziye Burcak; Grivas, Petros; de Wit, Ronald; Castellano, Daniel E.; Powles, Thomas; Vuky, Jacqueline; Zhao, Yujie; O'Hara, Karen; Okpara, Chinyere E.; Franco, Sonia; Moreno, Blanca Homet; Zolnierek, Jakub; Siefker-Radtke, Arlene O. Share Save
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Msaouel, Pavlos; Sweis, Randy F.; Bupathi, Manojkumar; Heath, Elisabeth; Goodman Jr, Oscar B.; Hoimes, Christopher J.; Milowsky, Matthew I.; Davis, Nancy; Kalebasty, Arash Rezazadeh; Picus, Joel; Shaffer, David; Mao, Shifeng; Adra, Nabil; Yorio, Jeffrey; Gandhi, Sunil; Grivas, Petros; Siefker-Radtke, Arlene; Yang, Rui; Latven, Lisa; Olson, Peter; Chin, Curtis D.; Der-Torossian, Hirak; Mortazavi, Amir; Iyer, Gopa Share Save
Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines Flaig, Thomas W.; Spiess, Philippe E.; Abern, Michael; Agarwal, Neeraj; Bangs, Rick; Buyyounouski, Mark K.; Chan, Kevin; Chang, Sam S.; Chang, Paul; Friedlander, Terence; Greenberg, Richard E.; Guru, Khurshid A.; Herr, Harry W.; Hoffman-Censits, Jean; Kaimakliotis, Hristos; Kishan, Amar U.; Kundu, Shilajit; Lele, Subodh M.; Mamtani, Ronac; Mian, Omar Y.; Michalski, Jeff; Montgomery, Jeffrey S.; Parikh, Mamta; Patterson, Anthony; Peyton, Charles; Plimack, Elizabeth R.; Preston, Mark A.; Richards, Kyle; Sexton, Wade J.; Siefker-Radtke, Arlene O.; Stewart, Tyler; Sundi, Debasish; Tollefson, Matthew; Tward, Jonathan; Wright, Jonathan L.; Cassara, Carly J.; Gurski, Lisa A. Share Save
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations Necchi, Andrea; Ramlau, Rodryg; Falcon Gonzalez, Alejandro; Chaudhry, Arvind; Todenhoefer, Tilman; Tahbaz, Rana; Fontana, Elisa; Giannatempo, Patrizia; Deville, Jean-Laurent; Pouessel, Damien; Yoon, Shinkyo; Powles, Thomas; Bernat, Mathieu; Hackl, Manuel; Marszewska, Michalina; McKernan, Phil; Saulay, Mikael; Scaleia, Federica; Engelhardt, Marc; Loriot, Yohann; Siefker-Radtke, Arlene; De Santis, Maria Share Save
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial Matsubara, Nobuaki; de Wit, Ronald; Balar, Arjun Vasant; Siefker-Radtke, Arlene O.; Zolnierek, Jakub; Csoszi, Tibor; Shin, Sang Joon; Park, Se Hoon; Atduev, Vagif; Gumus, Mahmut; Su, Yu -Li; Karaca, Saziye Burcak; Cutuli, Hernan Javier; Sendur, Mehmet A. N.; Shen, Liji; O'Hara, Karen; Okpara, Chinyere E.; Franco, Sonia; Moreno, Blanca Homet; Grivas, Petros; Loriot, Yohann Share Save
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience Sood, Akshay; Rudzinski, Jan K.; Labbate, Craig V.; Hensley, Patrick J.; Bree, Kelly K.; Guo, Charles C.; Alhalabi, Omar; Campbell, Matthew T.; Siefker-Radtke, Arlene O.; Navai, Neema; Dinney, Colin P. N.; Gao, Jianjun; Kamat, Ashish M. Share Save
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial Siefker-Radtke, A. O.; Matsubara, N.; Park, S. H.; Huddart, R. A.; Burgess, E. F.; Ozguroglu, M.; Valderrama, B. P.; Laguerre, B.; Basso, U.; Triantos, S.; Akapame, S.; Kean, Y.; Deprince, K.; Mukhopadhyay, S.; Loriot, Y. Share Save
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract Alhalabi, Omar; Wilson, Nathaniel; Xiao, Lianchun; Lin, Yiyun; Khandelwal, Jaanki; Moussa, Mohammad Jad; Msaouel, Pavlos; Navai, Neema; Gao, Jianjun; Kamat, Ashish M.; Pilie, Patrick; Shah, Amishi Y.; Goswami, Sangeeta; Matin, Surena; Kovitz, Craig; Holla, Vijaykumar; Guo, Charles; Czerniak, Bogdan; Logothetis, Christopher; Corn, Paul G.; Dinney, Colin P. N.; Campbell, Matthew T.; Hansel, Donna E.; Tannir, Nizar M.; Siefker-Radtke, Arlene O. Share Save
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma Loriot, Yohann; Matsubara, Nobuaki; Park, Se Hoon; Huddart, Robert A.; Burgess, Earle F.; Houede, Nadine; Banek, Severine; Guadalupi, Valentina; Ku, Ja Hyeon; Valderrama, Begona P.; Tran, Ben; Triantos, Spyros; Kean, Yin; Akapame, Sydney; Deprince, Kris; Mukhopadhyay, Sutapa; Stone, Nicole L.; Siefker-Radtke, Arlene O. Share Save
Share Save
Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations Matsubara, N.; Loriot, Y.; Burgess, E. F.; Park, S. H.; Huddart, R. A.; Ku, J. H.; Tran, B.; Triantos, S.; Deprince, K.; Mukhopadhyay, S.; Hemaya, R.; Zhuo, J.; Siefker-Radtke, A. O. Share Save
Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH) McGregor, B. A.; Campbell, M. T.; Huang, J.; Xie, W.; Bilen, M. A.; Mortazavi, A.; Ravi, P.; Shah, A.; Einstein, D.; Sonpavde, G. P.; McKay, R. R.; Siefker-Radtke, A. O.; Bellmunt, J.; Choueiri, T. K. Share Save
Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study Loriot, Y.; Matsubara, N.; Huddart, R. A.; Houede, N.; Laguerre, B.; Guadalupi, V.; Ku, J. H.; Triantos, S.; Akapame, S.; Deprince, K.; Mukhopadhyay, S.; Siefker-Radtke, A. O. Share Save
Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt) Siefker-Radtke, A. O.; Matsubara, N.; Park, S. H.; Huddart, R. A.; Burgess, E. F.; Ozguroglu, M.; Perez Valderrama, B.; Triantos, S.; Akapame, S.; Kean, Y.; Deprince, K.; Mukhopadhyay, S.; Loriot, Y. Share Save
Share Save
A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress) Iyer, Gopa; Siefker-Radtke, Arlene; Milowsky, Matthew; Shore, Neal; Gao, Xin; Reimers, Melissa A.; Hahn, Noah; Cosman, Rasha; Matsubara, Nobuaki; Necchi, Andrea; Robbrecht, Debbie; Vinceneux, Armelle; Grande, Enrique; Lee, Jae-Lyun; Zhang, Tian; Guren, Tormod; Lauer, Ulrich M.; Sarfaty, Michal; Eigl, Bernhard; Hussain, Syed; Zhao, Xiang; Balar, Arjun V.; Francese, Kaitlyn; Widau, Ryan; Garmezy, Benjamin Share Save
Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Siefker-Radtke, Arlene O.; Necchi, Andrea; Park, Se Hoon; Garcia-Donas, Jesus; Huddart, Robert A.; Burgess, Earle F.; Fleming, Mark T.; Kalebasty, Arash Rezazadeh; Mellado, Begona; Varlamov, Sergei; Joshi, Monika; Duran, Ignacio; Tagawa, Scott T.; Zakharia, Yousef; Qi, Keqin; Akapame, Sydney; Triantos, Spyros; O'Hagan, Anne; Loriot, Yohann Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
